Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Gilead unveils...

    Gilead unveils promising hepatitis C, fatty liver data; setbacks elsewhere

    Written by savita thakur thakur Published On 2016-10-22T11:50:37+05:30  |  Updated On 22 Oct 2016 11:50 AM IST
    Gilead unveils promising hepatitis C, fatty liver data; setbacks elsewhere

    Gilead Sciences Inc announced high cure rates across all types of hepatitis C in late stage studies testing a triple drug combination, and said another experimental drug showed promise in reducing liver scarring known as fibrosis in a mid stage trial.


    The company said it planned to advance the drug, called GS-4997 or selonsertib, into Phase III trials against the fatty liver disease known as NASH, or nonalcoholic steatohepatitis, that is reaching epidemic proportions in the United States and elsewhere. The drug was tested in combination with Gilead's experimental anti-fibrotic drug simtuzumab.


    Gilead shares rose more than 1 percent to $74.18.


    But GS-4997 failed to achieve the main goal of midstage trials for pulmonary arterial hypertension or diabetic kidney disease based on preliminary data analysis, the company said.


    "Due to insufficient evidence of efficacy, Gilead has decided not to pursue Phase III studies of GS-4997 in PAH or DKD at this time," Gilead said in a statement.


    A quartet of Phase III trials tested Gilead's Sovaldi in combination with experimental antiviral drugs velpatasvir and voxilaprevir across hepatitis C genotypes 1 through 6 in previously untreated patients and those who failed prior therapy. The trials included patients with and without advanced liver damage known as cirrhosis.


    Across the four trials, the pangenotypic triple combination achieved cure rates of between 95 percent and 97 percent over either eight or 12 weeks of treatment.


    The three drugs each use different mechanisms to prevent the virus from replicating in the blood. Gilead's big-selling two-drug combination Harvoni, which also includes Sovaldi, treats genotype 1, the most common in the United States, as well as genotypes 4, 5 and 6 with one pill a day.


    In the trial of 72 patients with NASH and moderate to severe fibrosis, 43 percent who got 18 milligrams of GS-4997 plus simtuzumab achieved at least a one-stage improvement in fibrosis. With a 6 mg dose of GS-4997 plus simtuzumab, 30 percent experienced such a fibrosis improvement, according to preliminary data after 24 weeks of treatment.


    "We believe this data, which raises the likelihood Gilead participates in multi-billion dollar markets beyond HIV and hepatitis C in the medium-term, should start to improve sentiment" for the company, Jefferies analyst Brian Abrahams said in a research note.


    Overall, GS-4997 was well tolerated with no dose-related increase in the incidence of treatment-related adverse events or serious adverse events, the company said.

    anti-fibrotic drugdiabetic kidney diseasefatty liver diseaseGileadGS-4997hepatitis CHIVhypertensionkidney diseasePulmonary arterial hypertensionselonsertib
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok